Education and Training
Comparison of PET/CT vs. PET/MRI Using 2 Radiopharmaceuticals
This clinical trial studies how well positron emission tomography (PET)/computed tomography (CT) works compared to PET/magnetic resonance imaging (MRI) in evaluating patients with cancer. PET/CT and PET/MRI may determine which scanner is best for the patient's type of cancer and other types of cancers.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Ga-68-DOTA-TATE
- drug: F-18 FDG
- device: Positron Emission Tomography / Computed Tomography (PET/CT) Scan
- device: Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Scan
Eligibility
INCLUSION CRITERIA
- Cancer diagnosis
- Capable of complying with study procedures
- Able to remain still for duration of imaging procedure (approximately 90 minutes
total)
- Written informed consent
EXCLUSION CRITERIA
- Pregnant or nursing
- Metallic implants
- Impaired renal function
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Not Recruiting